SAN DIEGO, Aug. 9, 2019 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP, is investigating potential claims
against Amarin Corporation plc ("Amarin") (NASDAQ: AMRN) for
violations of federal securities laws.
On August 8, 2019, Amarin
announced that it received notice from the FDA that it plans to
hold an advisory committee meeting, tentatively scheduled for
November 14, 2019, in connection with
its review of the pending supplemental new drug application for
expansion of Vascepa. The Company stated that the FDA's
deadline for making an approval decision on Vascepa would
likely be extended.
Just one week earlier, on July 31,
2019, Amarin said it was unlikely that the FDA
would proceed with an advisory panel review regarding approval
of Vascepa and anticipated a September 28, 2019 approval.
Following this news, Amarin stock was trading down over 20% in
premarket trading on August 9,
If you recently purchased Amarin and lost money, realized or
unrealized on your investment, and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(email@example.com) by email or phone at 619-814-4471. If
emailing, please include a phone number.
Additionally, you can [click here to join this
action]. There is no cost or obligation to you.
About Johnson Fistel,
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[click here to join this action]
SOURCE Johnson Fistel, LLP